Endo USA buprenorphine injection recalled for particulate matter contamination
Endo USA is recalling certain batches of buprenorphine hydrochloride 0.3 mg/mL injection due to the presence of particulate matter identified as buprenorphine free base in the vials. The affected lots are 84132 (expiration 02/28/2027) and 87693 (expiration 03/31/2027). No injuries have been reported.
From the FDA notice · Read the official notice ↗
Update since first reported
- Nov 1, 2026Hazard description updated
What to do
- Check your buprenorphine vials against the lot numbers and expiration dates listed in this recall.
- Do not use vials from lot 84132 or 87693.
- Contact your pharmacy or healthcare provider for a replacement or alternative.
- Report any use of recalled product to the FDA MedWatch program or your healthcare provider.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
Details
- Units affected
- 34,293 vials
- Illnesses reported
- None reported
- Manufactured in
- 870 Parkdale Rd, Rochester, MI, United States
- Classification
- Class II
- Recall number
- D-0527-2026
In the FDA's words
- Description
- Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05. Crystallization; identified as Buprenorphine free base Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027 Distribution: USA Nationwide Affected quantity: 34,293 vials
- Hazard
- Crystallization; identified as Buprenorphine free base